BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths.
I n cardiovascular outcomes trials, the primary efficacy assessment is usually based on an intervention delaying the time to first occurrence of an event included in a composite of related nonfatal and fatal (i.e., death) events. In this setting, patients are typically encouraged to remain on randomized therapy after a first reported nonfatal event, such that treatment may continue to modify the risk of subsequent nonfatal and fatal events. Consequently, an analysis involving only the first event may not capture the totality of the clinical impact of an intervention. Furthermore, the burden of a disease process may be best assessed by all of the events experienced by a patient, as those occurring after the first add to morbidity, mortality, and health care expenditures.
Several reports have demonstrated the benefits of intensive statin therapy on reducing first and subsequent events in composites consisting of nonfatal cardiovascular events and all-cause or cause-specific death in patients with stable coronary heart disease or an acute coronary syndrome (ACS) (1-5); similar findings have been reported with other drug classes (6, 7) . In trials involving these patient populations, the majority of patients are censored due to surviving the follow-up period. An important additional source of censoring that may not be fully appreciated when evaluating the effect of an intervention on nonfatal events is the occurrence of death, which, unlike other types of censoring, prevents both the observation and occurrence of subsequent nonfatal events. the occurrence of death may violate the noninformative censoring assumption that is integral to statistical methods typically used to analyze total events. This can lead to erroneous estimates of nonfatal event risk, and is especially problematic if there is an imbalance in the number of deaths between treatment groups.
As previously reported, when added to highintensity or maximum-tolerated statin therapy after ACS, alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer deaths relative to placebo in the ODYSSEY
OUTCOMES (Evaluation of Cardiovascular Outcomes
After an Acute Coronary Syndrome During Treatment With Alirocumab) trial (8) . To address the previously mentioned issues in the analysis of total events, we utilized a novel approach to jointly model total nonfatal cardiovascular and fatal events in a prespecified analysis of the study, allowing for the possibility that patients may experience multiple related nonfatal events. The method formally quantifies the association between nonfatal events and death while accounting for competing deaths that prevent followup for nonfatal events, resulting in a more accurate relative estimate (i.e., hazard ratio [HR]) for nonfatal event risk. Our hypothesis was that alirocumab reduces total events following ACS.
METHODS
Details of the study design (9) and primary efficacy and safety results (8) Szarek et al. Given the previously reported observation that the absolute benefit of alirocumab on the study primary efficacy endpoint was greater among patients with higher LDL-C at study entry, a post hoc analysis examined possible heterogeneity in the treatment effect on total nonfatal cardiovascular events and deaths in subgroups defined by LDL-C at randomization ($100 mg/dl vs. <100 mg/dl). All nonfatal cardiovascular events and deaths included in the analyses were adjudicated by an independent committee blinded to treatment assignment.
In this analysis, we applied a joint semiparametric model (sometimes referred to as a frailty model) that allows for multiple nonfatal cardiovascular events within a given patient, while simultaneously assessing and adjusting for possible informative censoring of the nonfatal event process by death. The model provides separate hazard functions for nonfatal events and fatal events, linked by a shared frailty (10).
The frailty random effect accounts for patient risk heterogeneity and the correlation between nonfatal events within a patient and is also included in the fatal event function. In the latter case, the frailty random effect is multiplied exponentially by an association parameter that quantifies the strength of the relationship between the nonfatal and fatal event processes. Specifically, an association parameter value equal to 0 indicates that death is noninformative for nonfatal events, whereas a value For model convergence purposes, for a given patient, a nonfatal event that occurred on the same day as death was excluded, and a maximum of 1 nonfatal event was allowed to occur on a given day.
With these conventions, all nonfatal events and deaths within a given patient have distinct event times from randomization.
Nonparametric mean cumulative function curves
were created for total nonfatal cardiovascular events.
The mean cumulative function represents the expected (i.e., mean) cumulative number of events for a patient at a given point in time after randomization. For comparative purposes, Kaplan-Meier curves were also created for first nonfatal events Szarek et al. Comparing groups with at least 1 event, patients with multiple events or an only event of death had higher Szarek et al. Total Event Reduction in ODYSSEY OUTCOMES 2.0 years) after randomization, death occurred as a third event in 6.2% and 6.6%, respectively, of the patients in the alirocumab and placebo groups.
Qualitatively, these data suggest that each successive prior nonfatal cardiovascular event is associated with an increased subsequent risk for death. The joint model ( Szarek et al. Mean cumulative function curves depict the expected total number of nonfatal cardiovascular (CV) events for a given patient in the placebo and alirocumab groups at a given time after randomization. At 4 years, the estimates are 0.357 and 0.301, respectively. In contrast, the expected proportions of patients with a first nonfatal CV event in the placebo and alirocumab groups were 0.183 and 0.160, respectively. Szarek et al. 
DISCUSSION
The ODYSSEY OUTCOMES trial demonstrated that adding the PCSK9 monoclonal antibody alirocumab to intensive statin therapy decreases the first occurrence of major adverse cardiovascular events compared with placebo (8) . The present analysis illustrates that this treatment effect is magnified when total nonfatal cardiovascular events and death are considered, with approximately twice as many total as first events prevented. Therefore, while the efficacy of alirocumab treatment after ACS was established on analysis of time to first primary endpoint event, the efficiency of the intervention to reduce morbidity and mortality after ACS, and its benefit to reduce the total burden of disease and health care costs, are best reflected by an analysis of total events. These findings mirror the pattern observed in prior trials of statins or ezetimibe in patients with coronary heart disease or ACS (1-5), indicating the value of Szarek et al. evaluating any long-term lipid-lowering therapy on the basis of total event modification. Szarek et al. Total Event Reduction in ODYSSEY OUTCOMES F E B R U A R Y 5 , 2 0 1 9 : 3 8 7 -9 6
